Skip to main content
SpringerLink
Log in

Comment on: "A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 12 October 2022

The Original Article was published on 14 July 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Villa-Zapata L, Gómez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disproportionality analysis of drug–drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022. https://doi.org/10.1007/s40264-022-01200-4.

    Article  PubMed  Google Scholar 

  2. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519–23. https://doi.org/10.1002/pds.1001.

    Article  PubMed  Google Scholar 

  3. Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22:347. https://doi.org/10.1093/bib/bbab347.

    Article  Google Scholar 

  4. van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999;47:689–93. https://doi.org/10.1046/j.1365-2125.1999.00957.x.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting drug–drug interactions using spontaneous reporting systems. Front Pharmacol. 2019;10:1319. https://doi.org/10.3389/fphar.2019.01319.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27:3057–70. https://doi.org/10.1002/sim.3247.

    Article  PubMed  Google Scholar 

  7. Uppsala Monitoring Centre (UMC). The UMC Measures of Disproportionate Reporting. Available online: https://who-umc.org/media/164041/measures-of-disproportionate-reporting_2016.pdf. Accessed 20 July, 2022.

  8. Noguchi Y, Tachi T, Teramachi H. Comparison of signal detection algorithms based on frequency statistical model for drug–drug interaction using spontaneous reporting systems. Pharm Res. 2020;37:86. https://doi.org/10.1007/s11095-020-02801-3.

    Article  CAS  PubMed  Google Scholar 

  9. Fujita T. Signal detection of adverse drug reactions. Jpn J Pharmacoepidemiol. 2009;14:27–36. https://doi.org/10.3820/jjpe.14.27.

    Article  Google Scholar 

  10. Urushihara H. Basic dos and don’ts in applying signal detection methods to spontaneous reporting systems databases. Jpn J Drug Inform. 2019;21:135–41. https://doi.org/10.11256/jjdi.21.135.

    Article  Google Scholar 

  11. Noguchi Y, Yoshizawa S, Aoyama K, Kubo S, Tachi T, Teramachi H. Verification of the “upward variation in the reporting odds ratio scores” to detect the signals of drug–drug interactions. Pharmaceutics. 2021;13:1531. https://doi.org/10.3390/pharmaceutics13101531.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, 501-1196, Japan

    Yoshihiro Noguchi

Authors
  1. Yoshihiro Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Noguchi.

Ethics declarations

Authors' contribution

YN participated in the interpretation of the study and in the preparation of this letter.

Funding

This reanalysis was supported by JSPS KAKENHI Grant Number 22K12890.

Conflicts of interest

YN declares that there is no competing interest.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noguchi, Y. Comment on: "A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)". Drug Saf 45, 1551–1552 (2022). https://doi.org/10.1007/s40264-022-01240-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-022-01240-w

Search

Navigation